Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles

Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family– plays a substantial role in HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients. However, the mechanism through which...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Vanesa G., O'Neill, Sadhbh, Salimu, Josephine, Breslin, Susan, Clayton, Aled, Crown, John, O'Driscoll, Lorraine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706614/
https://www.ncbi.nlm.nih.gov/pubmed/29209569
http://dx.doi.org/10.1080/2162402X.2017.1362530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706614/
https://www.ncbi.nlm.nih.gov/pubmed/29209569
http://dx.doi.org/10.1080/2162402X.2017.1362530

Ejemplares similares